Search Within

Erin M McGovern

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (10)
  2. Journal Article (7)
Groups
  1. Adult Leukemia (17)
  2. Center for Hematologic Malignancies (17)
  3. Department of Medicine (17)
  4. Executive Committee, Center for Hematologic Malignancies (17)
  5. GSK Faculty (17)
  6. Hematologic Malignancies, Division of (17)

More Groups

People
  1. Ross Levine (17)
  2. Minal Patel (9)
  3. Noushin Rahnamay Farnoud (9)
  4. Andrew Dunbar (7)
  5. Christopher Famulare (7)
  6. Martin Tallman (7)

More People

Years
  1. 2023 (2)
  2. 2022 (2)
  3. 2020 (3)
  4. 2019 (5)
  5. 2018 (5)
Publications
  1. Blood (11)
  2. American Journal of Hematology (1)
  3. Blood Advances (1)
  4. Cancer Cell (1)
  5. Clinical Cancer Research (1)
  6. Haematologica (1)

More Publications

Publishers
  1. American Society of Hematology (12)
  2. American Association for Cancer Research (1)
  3. Cell Press (1)
  4. Elsevier Ltd (1)
  5. Ferrata Storti Foundation (1)
  6. John Wiley & Sons, Inc. (1)

Results (17)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Identifying cytokine biomarkers of response to pegylated-interferon therapy in polycythemia vera and essential thrombocythemia: Correlative analysis from the MPN-RC 111/112 trials
    Meeting Abstract

    Dunbar, A.; Kosiorek, H. E.; Krishnan, A.; McGovern, E.; Park, Y.; Patel, M. A.; Singer Weinberg, R.; Yacoub, A.; Dueck, A. C.; Mascarenhas, J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia
    Journal Article

    Xiao, W.; Goldberg, A. D.; Famulare, C. A.; Devlin, S. M.; Nguyen, N. T.; Sim, S.; Kabel, C. C.; Patel, M. A.; McGovern, E. M.; Patel, A.; more...
    Haematologica (2019)

    Fulltext@MSK | Save
  • Loss of plasmacytoid dendritic cell differentiation is highly predictive for persistent measurable residual disease and poor outcomes in acute myeloid leukemia
    Meeting Abstract

    Xiao, W.; Goldberg, A. D.; Famulare, C.; Delvin, S.; Patel, M.; McGovern, E.; Patel, A.; Schulman, J.; Dunbar, A.; Epstein-Peterson, Z. D.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Early detection and molecular characterization of therapy-related leukemia in children reveals patterns of disease transformation and guides future surveillance protocols
    Meeting Abstract

    Spitzer, B.; Gundem, G.; Farnoud, N.; Millard, N.; McGovern, E.; Patel, M.; Levine, M.; Medina, J.; Zhou, Y.; Arango Ossa, J. E.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Evaluation of combination tagraxofusp (SL-401) and hypomethylating agent (HMA) therapy for the treatment of chronic myelomonocytic leukemia (CMML)
    Meeting Abstract

    Krishnan, A.; Li, B.; Pagane, M.; McGovern, E.; Stone-Molloy, Z.; Chen, J.; Brooks, C.; Levine, R. L.; Rampal, R. K.
    Blood (2018)

    Fulltext@MSK | Save
  • Molecular predictors and current management of minimal residual disease (MRD) following induction chemotherapy for acute myeloid leukemia (AML)
    Meeting Abstract

    Goldberg, A. D.; Famulare, C.; Devlin, S. M.; Farnoud, N.; Menghrajani, K.; Patel, M.; Cai, S.; Dunbar, A.; Epstein-Peterson, Z. D.; McGovern, E.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms
    Journal Article

    Kleppe, M.; Koche, R.; Zou, L.; van Galen, P.; Hill, C. E.; Dong, L.; De Groote, S.; Papalexi, E.; Hanasoge Somasundara, A. V.; Cordner, K.; more...
    Cancer Cell (2018)

    Fulltext@MSK | Save